- Home
- WLFC vs CVAC Comparison
WLFC vs CVAC Comparison
Compare WLFC & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLFC
- CVAC
- Stock Information
- Founded
- WLFC 1985
- CVAC 2000
- Country
- WLFC United States
- CVAC Germany
- Employees
- WLFC N/A
- CVAC N/A
- Industry
- WLFC Industrial Specialties
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- WLFC Consumer Discretionary
- CVAC Health Care
- Exchange
- WLFC Nasdaq
- CVAC Nasdaq
- Market Cap
- WLFC 1.2B
- CVAC 1.2B
- IPO Year
- WLFC 1996
- CVAC 2020
- Fundamental
- Price
- WLFC $149.03
- CVAC $5.39
- Analyst Decision
- WLFC
- CVAC Hold
- Analyst Count
- WLFC 0
- CVAC 3
- Target Price
- WLFC N/A
- CVAC $6.83
- AVG Volume (30 Days)
- WLFC 57.1K
- CVAC 632.4K
- Earning Date
- WLFC 11-03-2025
- CVAC 08-15-2025
- Dividend Yield
- WLFC 0.67%
- CVAC N/A
- EPS Growth
- WLFC 30.03
- CVAC N/A
- EPS
- WLFC 16.84
- CVAC 1.01
- Revenue
- WLFC $637,163,000.00
- CVAC $599,540,810.00
- Revenue This Year
- WLFC $16.17
- CVAC N/A
- Revenue Next Year
- WLFC $4.88
- CVAC $24.04
- P/E Ratio
- WLFC $8.85
- CVAC $5.36
- Revenue Growth
- WLFC 32.40
- CVAC 675.15
- 52 Week Low
- WLFC $97.54
- CVAC $2.37
- 52 Week High
- WLFC $235.43
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- WLFC 50.48
- CVAC 49.09
- Support Level
- WLFC $143.39
- CVAC $5.33
- Resistance Level
- WLFC $157.55
- CVAC $5.48
- Average True Range (ATR)
- WLFC 4.92
- CVAC 0.04
- MACD
- WLFC -0.98
- CVAC -0.01
- Stochastic Oscillator
- WLFC 39.55
- CVAC 38.89
About WLFC Willis Lease Finance Corporation
Willis Lease Finance Corp, with its subsidiaries, is a lessor and servicer of commercial aircraft and aircraft engines. The company has two reportable business segments, which include Leasing and Related Operations and Spare Parts Sales. A majority of its revenue is generated from the Leasing and Related Operations segment, which involves acquiring and leasing, under operating leases, commercial aircraft, aircraft engines, and other aircraft equipment and the selective purchase and resale of commercial aircraft engines, aircraft equipment, and other related businesses. Geographically, the company derives maximum revenue from the United States, followed by Europe, Asia-Pacific (excluding India), India, South America, Canada, Central America, and the Middle East.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.